TSRL Welcomes Lisa Crandall as Senior Scientific Advisor

TSRL is pleased to announce that Lisa Crandall has joined the company as a consultant Senior Scientific Advisor, bringing more than 25 years of hands-on pharmaceutical experience across formulation, analytical development, clinical manufacturing, regulatory strategy, and post-approval lifecycle management.

Crandall’s background spans the full journey of drug development, from preclinical formulation and analytical method development to Module 3 regulatory submissions and global CMC strategy. Her expertise strengthens TSRL’s ability to support biotech, pharma, and academic teams working to advance complex drug development programs with greater clarity and confidence.

“Lisa brings the kind of deep CMC knowledge and practical development experience that can make an immediate impact for our clients,” said Dr. Elke Lipka, President and CEO of TSRL. “She understands both the science and the strategy behind successful drug development, and her perspective will be extremely valuable as we continue to support teams moving from early development toward clinical and regulatory milestones.”

Crandall began her career at Parke-Davis and Pfizer before joining Velesco Pharma as its first employee. During her 16 years with Velesco, she helped build and lead a team that grew alongside some of the industry’s most complex development programs, including a decade-long project that resulted in an approved treatment for Duchenne muscular dystrophy. 

She later served as Senior Director and Site Head of the Pace Life Sciences Ann Arbor location before founding her consulting firm, Strategic CMC Insights.

“TSRL has a strong reputation for scientific depth, integrity, and practical problem solving,” said Crandall. “I’m excited to work with the team and contribute to programs where thoughtful CMC strategy, formulation expertise, and regulatory insight can help move promising therapies forward.”

Crandall holds a Bachelor of Science in Biochemistry from the University of Michigan and a Master of Science in Pharmaceutical Sciences from the University of Nebraska Medical Center. She also holds graduate certificates in International Biopharmaceutical Regulatory Affairs from Northeastern University and Biotech Project Management.

Her CMC regulatory experience includes submissions accepted in the United States, Europe, Canada, Australia, and the United Kingdom. She brings a rare combination of technical knowledge, regulatory fluency, and hands-on development leadership to TSRL’s growing advisor network.

As a consultant Senior Scientific Advisor, Crandall will support TSRL clients and internal teams with CMC strategy, formulation development, analytical considerations, regulatory planning, and program-level guidance.

Her appointment further strengthens TSRL’s ability to serve as a development partner for organizations navigating critical preclinical and early clinical development decisions. To learn more about TSRL’s scientific advisory team and preclinical development services, please connect with us at https://www.tsrlinc.com/contact.